Patents by Inventor Christine Ambrose

Christine Ambrose has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF MODULATING IMMUNE RESPONSES USING BCMA POLYPEPTIDE
    Publication number: 20200095305
    Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
    Type: Application
    Filed: October 16, 2019
    Publication date: March 26, 2020
    Applicants: Biogen MA Inc., Topotarget Switzerland SA
    Inventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider, Jeffrey Thompson
  • Methods of modulating immune responses using BCMA polypeptide
    Patent number: 10494416
    Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: December 3, 2019
    Assignees: Biogen MA Inc., Topotarget Switzerland SA
    Inventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider, Jeffrey Thompson
  • METHODS OF MODULATING IMMUNE RESPONSES USING BCMA POLYPEPTIDE
    Publication number: 20180273605
    Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
    Type: Application
    Filed: May 15, 2017
    Publication date: September 27, 2018
    Applicants: Biogen MA Inc., Topotarget Switzerland SA
    Inventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider, Jeffrey Thompson
  • Methods of treating autoimmune diseases using a B-cell maturation antigen (BCMA)
    Patent number: 9650430
    Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: May 16, 2017
    Assignee: BIOGEN, MA INC.
    Inventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider, Jeffrey Thompson
  • TACI AS AN ANTI-TUMOR AGENT
    Publication number: 20150218247
    Abstract: A method of treating a mammal for a condition associated with undesired cell proliferation comprising administering to said mammal an effective amount of a TACI reagent, wherein said reagent extends mean survival time of said mammal by about 10% or more as compared to the absence of administering the TACI reagent.
    Type: Application
    Filed: February 25, 2015
    Publication date: August 6, 2015
    Applicants: BIOGEN IDEC MA INC.
    Inventors: Christine Ambrose, Jeffrey Thompson, Paul Rennert, Pascal Schneider
  • BAFF RECEPTOR (BCMA), AN IMMUNOREGULATORY AGENT
    Publication number: 20150139992
    Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
    Type: Application
    Filed: August 6, 2014
    Publication date: May 21, 2015
    Applicants: TOPOTARGET SWITZERLAND SA, BIOGEN IDEC MA INC.
    Inventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider, Jeffrey Thompson
  • METHODS OF MODULATING IMMUNOLOGICAL RESPONSES BY ADMINISTERING TRUNCATED BAFF RECEPTORS
    Publication number: 20150023961
    Abstract: The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered O-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders.
    Type: Application
    Filed: July 28, 2014
    Publication date: January 22, 2015
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Christine Ambrose, Jeffrey Thompson, Yen-Ming Hsu, Dingyi Wen, Yaping Sun
  • Methods of screening for a compound that inhibits the interaction between BAFF and BCMA
    Patent number: 8828669
    Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: September 9, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider, Jeffrey Thompson
  • Method of treating B cell cancers by administering truncated BAFF receptors
    Patent number: 8821883
    Abstract: The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered O-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders.
    Type: Grant
    Filed: October 4, 2012
    Date of Patent: September 2, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Christine Ambrose, Jeffrey Thompson, Yen-Ming Hsu, Dingyi Wen, Yaping Sun
  • Method of treating immunological disorders by administering truncated BAFF receptors
    Patent number: 8303958
    Abstract: The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered 0-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: November 6, 2012
    Assignee: Biogen Idec MA Inc.
    Inventors: Christine Ambrose, Jeffrey Thompson, Yen-Ming Hsu, Dingyi Wen, Yaping Sun
  • TACI AS AN ANTI-TUMOR AGENT
    Publication number: 20120189634
    Abstract: A method of treating a mammal for a condition associated with undesired cell proliferation comprising administering to said mammal an effective amount of a TACI reagent, wherein said reagent extends mean survival time of said mammal by about 10% or more as compared to the absence of administering the TACI reagent.
    Type: Application
    Filed: March 9, 2011
    Publication date: July 26, 2012
    Inventors: Christine Ambrose, Jeffrey Thompson, Pascal Schneider, Paul Rennert
  • TRUNCATED BAFF RECEPTORS
    Publication number: 20110311530
    Abstract: The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered 0-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders.
    Type: Application
    Filed: August 19, 2011
    Publication date: December 22, 2011
    Inventors: Christine Ambrose, Jeffrey Thompson, Yen-Ming Hsu, Dingyi Wen, Yaping Sun
  • Truncated BAFF receptors
    Patent number: 8022182
    Abstract: The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered O-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders.
    Type: Grant
    Filed: February 11, 2010
    Date of Patent: September 20, 2011
    Assignee: Biogen Idec MA Inc.
    Inventors: Christine Ambrose, Jeffrey Thompson, Yen-Ming Hsu, Dingyi Wen, Yaping Sun
  • BAFF, inhibitors thereof and their use in the modulation of B-cell response
    Publication number: 20100233179
    Abstract: The invention provides methods for treating or preventing disorders associated with expression of BAFF comprising BAFF and fragments thereof, antibodies, agonists and antagonists.
    Type: Application
    Filed: September 30, 2009
    Publication date: September 16, 2010
    Inventors: Jeffrey Browning, Christine Ambrose, Fabienne MacKay, Jurg Tschopp, Pascal Schneider
  • Truncated BAFF Receptors
    Publication number: 20100184951
    Abstract: The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered O-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders.
    Type: Application
    Filed: February 11, 2010
    Publication date: July 22, 2010
    Inventors: Christine Ambrose, Jeffrey Thompson, Yen-Ming Hsu, Dingyi Wen, Yaping Sun
  • Truncated baff receptors
    Patent number: 7700317
    Abstract: The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered 0-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders.
    Type: Grant
    Filed: March 26, 2004
    Date of Patent: April 20, 2010
    Assignee: Biogen Idec Ma Inc.
    Inventors: Christine Ambrose, Jeffrey Thompson, Yen-Ming Hsu, Dingyi Wen, Yaping Sun
  • Methods of treating a tumor that expresses APRIL by administering BCMA
    Patent number: 7276241
    Abstract: A novel receptor in the TNF family is provided: APRIL-R. Chimeric molecules and antibodies to APRIL-R and methods of use thereof are also provided.
    Type: Grant
    Filed: April 2, 2002
    Date of Patent: October 2, 2007
    Assignees: Biogen Idec MA Inc., Apoxis SA
    Inventors: Pascal Schneider, Jeffrey Thompson, Teresa Cachero, Christine Ambrose, Paul Rennert
  • NOVEL RECEPTOR NUCLEIC ACIDS AND POLYPEPTIDES
    Publication number: 20060240518
    Abstract: Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided.
    Type: Application
    Filed: June 23, 2006
    Publication date: October 26, 2006
    Inventors: Christine Ambrose, Jeffrey Thompson
  • NOVEL RECEPTOR NUCLEIC ACIDS AND POLYPEPTIDES
    Publication number: 20060240517
    Abstract: Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided.
    Type: Application
    Filed: June 23, 2006
    Publication date: October 26, 2006
    Inventors: Christine Ambrose, Jeffrey Thompson
  • NOVEL RECEPTOR NUCLEIC ACIDS AND POLYPEPTIDES
    Publication number: 20060240520
    Abstract: Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided.
    Type: Application
    Filed: June 23, 2006
    Publication date: October 26, 2006
    Inventors: Christine AMBROSE, Jeffrey Thompson